Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
Status:
Recruiting
Trial end date:
2023-06-05
Target enrollment:
Participant gender:
Summary
This study will be conducted to support the registration of the lanreotide Autogel 120 mg
formulation in China for the treatment of GEP-NETs and treatment of clinical symptoms of
NETs.
The study will include a screening period of up to 4 weeks followed by a 48-week intervention
period. After completion of the main study period, approximately five participants will
continue in a self/partner injection cohort with lanreotide Autogel 120 mg every 28 days for
24 weeks.